RxDoctor Payments Data

Natasha Bell

Nurse Practitioner · Brandon, FLNPI 1629667670

Payments from drug & device makers

$2,738in general payments, 2019–2025

Across 125 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$688
  • Sanofi$433
  • Johnson & Johnson$367
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$205
  • Regeneron Healthcare Solutions, Inc.$141
  • Madrigal Pharmaceuticals$139
  • plus $765 from 17 others

What the payments were for

  • Food & beverage$2,53192%
  • Education$2078%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,738 in reported general payments places this provider in the 85th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$13,911
Medicare patients
123
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase46$89,540
GimotiMetoclopramide Hcl12$24,114
LinzessLinaclotide14$10,688
ClenpiqSod Picosulf/Mag Ox/Citric Ac36$6,143
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates87$5,485
Mesalamine ErMesalamine20$4,907
Budesonide DrBudesonide12$2,511
SutabSod Sulf/Pot Chloride/Mag Sulf14$2,292
Pantoprazole Sodium221$1,687
Famotidine65$988
Dicyclomine Hcl48$939
Dexlansoprazole DrDexlansoprazole16$872
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine20$535
Omeprazole26$399
Amitriptyline Hcl16$185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$688$100,22860 claims
Evoke Pharma, Inc.Gimoti$81$24,11412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →